NEW YORK, NY — January 21, 2026 — Leads & Copy —
Tempus AI, Inc. (NASDAQ: TEM) has launched Paige Predict, a suite of digital pathology applications that use AI to analyze hematoxylin and eosin (H&E) whole slide images. The solution helps inform testing decisions by predicting the presence or absence of clinically relevant biomarkers from a single H&E slide.
The AI-powered solution offers insights even when tissue samples are insufficient for full molecular profiling. The launch comes as demand for next-generation sequencing (NGS) and immunohistochemistry (IHC) testing increases, creating challenges due to limited tissue availability.
According to Tempus, when a sample is “quantity not sufficient” (QNS), patients may experience delays in receiving test results, potentially impacting treatment options. Paige Predict aims to address this by identifying biomarkers from H&E images, allowing clinicians to prioritize confirmatory tissue-based tests.
The solution analyzes H&E images to predict the likelihood of 123 biomarkers and oncogenic molecular pathways across 16 cancer types, including NSCLC, prostate, breast, pancreatic, and colorectal cancers.
The product was built using Paige’s foundation model and a combined, multimodal cohort from Tempus and Paige. The cohort contains de-identified data from over 200,000 patients. Results are automatically delivered with the clinical report to ordering physicians.
Dr. Ezra Cohen, Chief Medical Officer, Oncology at Tempus, stated that Paige Predict overcomes a major barrier in NGS by delivering actionable information to inform critical testing decisions when sequencing isn’t feasible.
Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and facilitates the discovery, development and delivery of optimal therapeutics.
“Tissue can be scarce, but insights don’t have to be,” said Ezra Cohen, MD, Chief Medical Officer, Oncology at Tempus.
Paige Predict was built using Paige’s foundation model and a combined, multimodal cohort from Tempus and Paige, which contains de-identified data on over 200,000 patients. The model has been rigorously validated to demonstrate performance, generalizability and robustness across multiple, diverse datasets, including a large-scale cohort from Tempus.
Tempus’ goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
Ezra Cohen, MD, Chief Medical Officer, Oncology at Tempus.
Source: Tempus AI, Inc.
